Literature DB >> 24837465

STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.

Robert S Ohgami1, Lisa Ma2, Ahmad Monabati3, James L Zehnder2, Daniel A Arber2.   

Abstract

Entities:  

Keywords:  B-cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma; CD30; STAT3; anaplastic large cell lymphoma; diffuse large B-cell lymphoma

Mesh：

Substances：

Year:  2014        PMID： 24837465      PMCID： PMC4077094          DOI： 10.3324/haematol.2013.101543

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism.

Authors:  Peter Cartwright; Cameron McLean; Allan Sheppard; Duane Rivett; Karen Jones; Stephen Dalton
Journal:  Development       Date:  2005-01-26       Impact factor: 6.868

3.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Authors:  B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

4.  Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.

Authors:  Derek Daigle; Cynthia Megyola; Ayman El-Guindy; Lyn Gradoville; David Tuck; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 5.  Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome.

Authors:  Yoshiyuki Minegishi; Masako Saito
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

6.  STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.

Authors:  Inbal Hazan-Halevy; David Harris; Zhiming Liu; Jie Liu; Ping Li; Xiaomin Chen; Sreejesh Shanker; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

Review 7.  Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis.

Authors:  Corinne M Silva
Journal:  Oncogene       Date:  2004-10-18       Impact factor: 9.867

Review 8.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

9.  High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma.

Authors:  Z L Wu; Y Q Song; Y F Shi; J Zhu
Journal:  J Hematol Oncol       Date:  2011-08-01       Impact factor: 17.388

10.  STAT3 is required for the gp130-mediated full activation of the c-myc gene.

Authors:  N Kiuchi; K Nakajima; M Ichiba; T Fukada; M Narimatsu; K Mizuno; M Hibi; T Hirano
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307
View more
  17 in total

1.  The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.

Authors:  Hanna L M Rajala; Thomas Olson; Michael J Clemente; Sonja Lagström; Pekka Ellonen; Tuija Lundan; David E Hamm; Syed Arshi Uz Zaman; Jesus M Lopez Marti; Emma I Andersson; Andres Jerez; Kimmo Porkka; Jaroslaw P Maciejewski; Thomas P Loughran; Satu Mustjoki
Journal:  Haematologica       Date:  2014-10-03       Impact factor: 9.941

2.  Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.

Authors:  Can Küçük; Bei Jiang; Xiaozhou Hu; Wenyan Zhang; John K C Chan; Wenming Xiao; Nathan Lack; Can Alkan; John C Williams; Kendra N Avery; Pınar Kavak; Anna Scuto; Emel Sen; Philippe Gaulard; Lou Staudt; Javeed Iqbal; Weiwei Zhang; Adam Cornish; Qiang Gong; Qunpei Yang; Hong Sun; Francesco d'Amore; Sirpa Leppä; Weiping Liu; Kai Fu; Laurence de Leval; Timothy McKeithan; Wing C Chan
Journal:  Nat Commun       Date:  2015-01-14       Impact factor: 14.919

3.  Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Authors:  Alexandra Nagy; Aparna Bhaduri; Nahid Shahmarvand; Jahanbanoo Shahryari; James L Zehnder; Roger A Warnke; Tariq Mughal; Siraj Ali; Robert S Ohgami
Journal:  Blood Adv       Date:  2018-03-13

4.  Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia.

Authors:  E Andersson; H Kuusanmäki; S Bortoluzzi; S Lagström; A Parsons; H Rajala; A van Adrichem; S Eldfors; T Olson; M J Clemente; A Laasonen; P Ellonen; C Heckman; T P Loughran; J P Maciejewski; S Mustjoki
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

Review 5.  Genomics of LGL leukemia and select other rare leukemia/lymphomas.

Authors:  Katharine B Moosic; Umadevi Paila; Kristine C Olson; Karolina Dziewulska; T Tiffany Wang; Jeffrey C Xing; Aakrosh Ratan; David J Feith; Thomas P Loughran; Thomas L Olson
Journal:  Best Pract Res Clin Haematol       Date:  2019-06-06       Impact factor: 3.020

6.  Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.

Authors:  Adam R Davis; Sara L Stone; Amanda R Oran; Robyn T Sussman; Siddharth Bhattacharyya; Jennifer J D Morrissette; Adam Bagg
Journal:  Mod Pathol       Date:  2020-12-12       Impact factor: 7.842

7.  Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.

Authors:  K M Kortuem; E Braggio; L Bruins; S Barrio; C S Shi; Y X Zhu; R Tibes; D Viswanatha; P Votruba; G Ahmann; R Fonseca; P Jedlowski; I Schlam; S Kumar; P L Bergsagel; A K Stewart
Journal:  Blood Cancer J       Date:  2016-02-26       Impact factor: 11.037

8.  Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.

Authors:  Heikki Kuusanmäki; Olli Dufva; Elina Parri; Arjan J van Adrichem; Hanna Rajala; Muntasir M Majumder; Bhagwan Yadav; Alun Parsons; Wing C Chan; Krister Wennerberg; Satu Mustjoki; Caroline A Heckman
Journal:  Oncotarget       Date:  2017-10-31

9.  STAT3 mutation impacts biological and clinical features of T-LGL leukemia.

Authors:  Antonella Teramo; Gregorio Barilà; Giulia Calabretto; Chiara Ercolin; Thierry Lamy; Aline Moignet; Mikael Roussel; Cédric Pastoret; Matteo Leoncin; Cristina Gattazzo; Anna Cabrelle; Elisa Boscaro; Sara Teolato; Elisa Pagnin; Tamara Berno; Elena De March; Monica Facco; Francesco Piazza; Livio Trentin; Gianpietro Semenzato; Renato Zambello
Journal:  Oncotarget       Date:  2017-06-27

Review 10.  JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Authors:  Jan Pencik; Ha Thi Thanh Pham; Johannes Schmoellerl; Tahereh Javaheri; Michaela Schlederer; Zoran Culig; Olaf Merkel; Richard Moriggl; Florian Grebien; Lukas Kenner
Journal:  Cytokine       Date:  2016-06-24       Impact factor: 3.861
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.